Federal probe underway, as UnitedHealth confirms collaboration with authorities
UnitedHealth Group, the nation's largest health insurer and Medicare Advantage provider, is currently under investigation by the U.S. Department of Justice (DOJ) for its billing practices within its Medicare Advantage program. The probe, which has been ongoing since mid-2025, involves both criminal and civil components, making it one of the most significant Medicare fraud investigations to date.
The investigation targets UnitedHealth's diagnosis coding practices, which influence payments from the federal government in the Medicare Advantage program, a privatized alternative to traditional Medicare. The inquiry raises concerns about alleged abuses where insurers purportedly inflate government reimbursements falsely, an issue central to whistleblower lawsuits and government inquiries in recent years.
The DOJ investigations come at a challenging time for UnitedHealth. The company has been under antitrust scrutiny over a $3.3 billion acquisition deal for a home-health services firm, Amedisys, and has faced various controversies and DOJ probes reported by media outlets like The Wall Street Journal. In May, the company's CEO, Andrew Witty, resigned abruptly, and the company withdrew its forecast entirely.
Despite the investigations, UnitedHealth maintains confidence in the accuracy of its billing and diagnosis practices, citing independent audits by the Centers for Medicare & Medicaid Services (CMS) that have verified their compliance and integrity. The company asserts that it is cooperating fully with the DOJ throughout the process.
As the nation's largest Medicare Advantage provider, any findings of wrongdoing or penalties could have significant financial and reputational consequences for UnitedHealth and may impact the Medicare Advantage program's regulatory environment broadly. The intensified DOJ scrutiny signals a heightened federal focus on Medicare Advantage fraud, possibly prompting broader reforms or oversight adjustments in the Medicare Advantage industry.
UnitedHealth Group, which ranked third in the Fortune 500 list of biggest U.S. companies with over $400 billion in revenue last year, operates a health insurance and pharmacy benefits management business, as well as a growing Optum business that provides care and technology support. The share price of UnitedHealth Group Inc. reached a new all-time high of $630 last fall but has since mostly shed value. On Thursday afternoon, the stock price was down more than 3%.
The investigations are centered around certain elements of UnitedHealth's business, and the company continues to operate as usual. UnitedHealthcare, a business of UnitedHealth Group, covers more than 8 million people as the nation's largest provider of Medicare Advantage plans. The company has a long record of responsible conduct and effective compliance.
UnitedHealth Group has full confidence in its practices and is committed to working cooperatively with the Department of Justice throughout the process. The company contacted the DOJ after reviewing media reports about the investigations. The Wall Street Journal reported in February that the probe focused on billing practices in recent months.
In a tragic turn of events, UnitedHealth Group Inc.'s CEO Brian Thompson was fatally shot in midtown Manhattan in December, and a suspect, Luigi Mangione, has been charged in connection with the shooting. The company is working through this difficult period while addressing the federal investigation.
- The government's investigation of UnitedHealth Group, a major player in the health-and-wellness sector and the nation's largest Medicare Advantage provider, is examining its diagnosis coding practices within the Medicare Advantage program.
- Microsoft, Amazon, and other technology companies may not be directly involved in this investigation, but the outcome could potentially influence the regulatory environment of the Medicare Advantage industry, an sector that integrates science and technology.
- The federal investigation, which has been ongoing since mid-2025, has uncovered concerns about alleged abuses involving inflated government reimbursements, a practice that has been a controversial issue in recent years in both the business and medical-conditions sectors.
- UnitedHealth Group, which ranks high in the Fortune 500 list and operates in health care, finance, and technology, is facing challenges, including an ongoing antitrust probe and the recent shooting of its CEO, Brian Thompson, in midtown Manhattan.
- The DOJ investigations could result in significant financial and reputational consequences for UnitedHealth Group, potentially impacting not only the company but also the Medicare Advantage program and the broader health care industry.
- Despite the probes and controversies, UnitedHealth Group asserts that it operates with responsible conduct and effective compliance, and it continues to cooperate fully with the DOJ throughout the investigation.
